Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis. [PDF]
Carmona-Segovia AD +5 more
europepmc +1 more source
Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension. [PDF]
Zhu YJ +13 more
europepmc +1 more source
Targeting the Hippo pathway in pulmonary arterial hypertension: emerging pharmacological strategies. [PDF]
Zheng D, Guo Y.
europepmc +1 more source
Reduced Circulating HIF-1α, HIF-2α, HIF-3α, and VHL Levels in Patients With Pulmonary Arterial Hypertension. [PDF]
Kan H +6 more
europepmc +1 more source
Transitioning From Oral to Intravenous Treprostinil in Pulmonary Arterial Hypertension: A Case Report. [PDF]
Cummings AM +3 more
europepmc +1 more source
Methamphetamine-Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management. [PDF]
Sood N +4 more
europepmc +1 more source
Pulmonary Arterial Hypertension
Abstract: This article discusses the pathophysiology, risk factors, clinical manifestations, diagnostics, and pharmacologic treatment of pulmonary arterial hypertension, as well as nursing considerations for caring for patients with this rare disease.
Paul M Hassoun
exaly +8 more sources
Related searches:
Pulmonary Arterial Hypertension
New England Journal of Medicine, 2004Harrison Farber +2 more
exaly +3 more sources
Pulmonary arterial hypertension
Medicina Clínica (English Edition), 2022Pulmonary arterial hypertension (PAH) is a rare disease characterized by adverse remodeling of the arterial tree leading to increased vascular resistance with subsequent increase in right ventricular afterload and eventual development of heart failure.
Raquel, Luna-López +2 more
openaire +2 more sources

